Spondyloarthritis & psoriatic arthritis
Patient-Reported Outcomes (PROs) and PRO Remission Rates in 12,262 Biologic-Naïve Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitors in Routine Care
Authors' conclusion
In 12,262 biologic-naïve patients with PsA, 6 months of treatment with a TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex, and age at onset of disease were observed, emphasizing the potential influence of factors other than disease activity on PROs.
Study context
- Population
- Biologic-naïve European real-world patients with PsA initiating a tumor necrosis factor inhibitor (TNFi) in routine care, 13 registries
- Participants
- 12,262 patients13 registries
- Exposure
- First TNFi vs Second TNFi vs Third TNFi
- Outcome
- PROs (pain, fatigue, PtGA by VAS or NRS; HAQ-DI) after TNFi initiation, and PRO remission rates (pain ≤ 1, fatigue ≤ 2, PtGA ≤ 2, HAQ-DI ≤ 0.5)
Methodological detailspooled registry data, real-world, 13 European registries, pooled analysis, LUNDEX-adjusted remission rates
- Pooled registry data
- Real-world
- 13 European registries
- Pooled analysis
- LUNDEX-adjusted remission rates
Main finding
As reported in the abstract
Median pain score (reduced by ≈50%)
6 to 3, 3, and 2
Median fatigue score
6 to 4, 4, and 3
Median patient global assessment (PtGA) score
6 to 3, 3, and 2
Median Health Assessment Questionnaire-Disability Index (HAQ-DI) score
0.9 to 0.5, 0.5, and 0.4
Observational data: associations, not effects.
Further findings
LUNDEX-adjusted remission rates for pain, fatigue, PtGA, HAQ-DI by treatment course · 6 months
- First TNFi (pain, fatigue, PtGA, HAQ-DI)
- 24%, 31%, 36%, and 43%
- Second TNFi (pain, fatigue, PtGA, HAQ-DI)
- 14%, 19%, 23%, and 29%
- Third TNFi (pain, fatigue, PtGA, HAQ-DI)
- 9%, 14%, 17%, and 20%
LUNDEX-adjusted remission rates for pain, fatigue, PtGA, HAQ-DI by disease duration (biologic-naïve) · 6 months
- Disease duration < 5 years
- 22%, 28%, 33%, and 42%
- Disease duration > 10 years
- 27%, 32%, 41%, and 43%
Remission rates for pain, fatigue, PtGA, HAQ-DI by sex
- Men
- 33%, 40%, 45%, and 56%
- Women
- 17%, 23%, 24%, and 32%
LUNDEX-adjusted pain remission rate by age at diagnosis · 6 months
- Aged < 45 years at diagnosis
- 29%
- Aged ≥ 45 years at diagnosis
- 18%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →